Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemoembolization Clear all
Completed Phase 2 Interventional

Self-Hypnotic Relaxation Therapy During Invasive Procedures

NCT00087841
View directory record Official record
Conditions
Uterine Neoplasms, Leiomyoma
Interventions
Self-hypnotic relaxation
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery

NCT00109954
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin, brachytherapy, yttrium Y 90 glass microspheres
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed

NCT00877071
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
LC Bead loaded with doxorubicin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 2, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

NCT06261814
View directory record Official record
Conditions
Liver Neoplasms
Interventions
Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization, Medical Chart Review
Drug · Procedure · Other
Lead sponsor
john eisenbrey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

NCT02764801
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 2, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

NCT03937830
View directory record Official record
Conditions
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Chemoembolization for Lung Tumors

NCT04200417
View directory record Official record
Conditions
Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
Interventions
Chemoembolization, Mitomycin C, Lipiodol, Embospheres
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Early Phase 1 Interventional

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

NCT03143270
View directory record Official record
Conditions
Liver Cancer
Interventions
Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
St Louis, Missouri • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 5:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

NCT00023868
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFIRI regimen, cisplatin, doxorubicin hydrochloride, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C
Drug
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
9
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions
Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
281
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 2, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

NCT06971991
View directory record Official record
Conditions
Transarterial Embolism, Transarterial Chemoembolization, Radioembolization
Interventions
qDSA Blood Flow Measurement
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

NCT02471313
View directory record Official record
Conditions
Liver Cancer, Liver Neoplasm, Hepatocellular Carcinoma, HCC
Interventions
[18F] FMISO
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 2, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Results available

LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma

NCT02524119
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
LEE011, Chemoembolization
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 2Phase 3 Interventional

Nonpharmacologic Analgesia for Invasive Procedures

NCT00010855
View directory record Official record
Conditions
Pain, Anxiety
Interventions
Self-hypnotic relaxation
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

NCT04340193
View directory record Official record
Conditions
Cancer, Hepatocellular
Interventions
nivolumab, ipilimumab, TACE
Drug · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Coronado, California • Washington D.C., District of Columbia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 2, 2026, 5:50 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NCT00539253
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
gadobenate dimeglumine (MultiHance)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 2, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

NCT01336985
View directory record Official record
Conditions
Neoplasm Metastases, Melanoma, Colorectal Neoplasms
Interventions
Irinotecan, Chemoembolization, Drug-Eluting Beads, Biopsy
Drug · Procedure · Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 84 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Early Phase 1 Interventional Results available

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

NCT01247298
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 2, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

NCT02513199
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SBRT, TACE
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 2, 2026, 5:50 AM EDT
Terminated Not applicable Interventional Results available

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

NCT02057874
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Stage A Adult Primary Liver Cancer (BCLC), Stage B Adult Primary Liver Cancer (BCLC)
Interventions
3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Device · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 2, 2026, 5:50 AM EDT
Terminated No phase listed Observational

Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

NCT01326390
View directory record Official record
Conditions
Kidney (Renal Cell) Cancer
Interventions
dTA/dBA C-arm fluoroscopy system with Dyna CT, DSA arteriogram- hepatic arteries, CO2 aortogram
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 2, 2026, 5:50 AM EDT
Withdrawn Not applicable Interventional

SBRT + TACE for Primary Hepatocellular Carcinoma

NCT00746655
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT), Transcatheter Arterial Chemoembolization (TACE)
Radiation · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 2, 2026, 5:50 AM EDT